



kayentis

The best of both worlds

SUCCESS STORY

EARLY PHASE



So intuitive to collect data
So effective to share information

CLIN FORM[®] FOR VAXINNATE CORP.

VAXINNATE CORPORATION



Vaxinnate Corporation is a biotechnology company pioneering breakthrough technology for developing novel and proprietary vaccines. Its technology has the

potential to significantly improve the potency, manufacturing capacity, and cost-effectiveness of vaccines.

Partnering effort: Phase II, open-label, escalating dose ranging study to evaluate the safety and immunogenicity of Vaxinnate's VAX125 influenza vaccine in community-living adults ≥ 65 years of age. The study's duration was two months and included 80 patients in four arms of 20 each at three U.S. sites.

Challenges:

- 1/ Vaxinnate wanted to rapidly deploy a **reliable clinical data-collection tool with minimal training requirements.**
- 2/ Vaxinnate also needed an intuitive, **easy-to-use tool** that could **unite a total of 18 doctors, nurses and monitors** in a **collaborative environment.**
- 3/ Vaxinnate further required the creation of a **complete audit trail for the study** that could be **available instantly.**

KAYENTIS is the #1 publisher and operator of digital pen and smart paper solutions for the healthcare industry.

These solutions, based on the KAYENTIS Digital Pen & Paper platform, combine the best of the physical and digital worlds: a very simple collection method (paper and pen) that offers the highest data reliability, plus all the advantages of electronic management (real-time data access, precise timestamping, audit trail features, alerts, and transmission of relevant information to each stakeholder).

Today, KAYENTIS solutions have been successfully deployed in **50 countries for more than 50,000 patients.**

KAYENTIS is a member of the MEDICEN, Lyon Biopôle, Pennsylvania BIO and BIO New Jersey clusters. KAYENTIS is an Anoto Platinum Partner, Oracle Partner and HP Solution Business Partner.

Find out more at www.kayentis.com



KAYENTIS is one of the leading world partners of **ANOTO**, and is certified Anoto Platinum Partner.

BENEFITS

- Reliability of data, real-time data to make ongoing critical decisions
- Traceability and data security via a secured web portal
- Every entry is time-stamped for a precise audit trail
- "The business model is win/win for both of us"

SUCCESS STORY

EARLY PHASE

WHAT THE EXPERTS ARE SAYING



David Taylor, M.D.

Chief Medical Officer
Vaxinnate Corporation

“ I am convinced that the outstanding Kayentis digital pen and paper system will remain at the cutting edge as we move forward together. As far as I know, there is no other available technology that offers the same critically important features as Kayentis. One reason I choose to work with Kayentis is because **they make me feel like they're really our partner. I can go back to Kayentis, tell its people what my issues are and know that they're paying close attention and listening very carefully to what I have to say.** ”

What are the most important benefits of the kayentis technology versus EDC and other digital-pen offerings?

“Especially with an escalating-dose study, obtaining **reliable, real-time data to make ongoing critical decisions** is absolutely essential. **The Kayentis Clin'Form® Digital Pen has two very important technical advantages over the competition.** First, it allows a user to dock his individual Pen as many times as he or she needs to, and every entry is time-stamped for a **precise audit trail.** Second, the Kayentis technology permits a **number of different people to enter information onto a single piece of paper Pen with their own individually assigned Digital Pen.** This is not the case with EDC or the other digital-pen vendors Vaxinnate considered. In

addition, **only Kayentis was able to customize its offering to suit our needs.** Kayentis, for example, developed a custom data board that allows us to track each patient with different doses, see the effects of dosage escalation in real-time, and then make go-forward decisions according to the data collected at three different clinical sites across the US”.

What about kayentis customer service: does it match the level of their technical superiority?

“**The Kayentis people are extremely responsive to us; they make me feel like we're in this together.** A huge CRO that has a sizable contract with a big pharmaceutical company might take our business and tell me how important it is to them, pointing out that 75% of their business comes from small companies like Vaxinnate. That may or may not be true, but **I am absolutely certain that my business is very important to Kayentis.**”

Does kayentis really understand your needs and wants?

“Another important reason that I chose to partner with Kayentis is because **their business model is a 'win/win' for both of us.** Most companies in the data-collection field do not sell a single product or service like Kayentis; those companies want to wrap data-collection around their other products and services, such as monitoring and data analysis. It's much more cost-effective for us because I buy what Kayentis is really good at. They don't sell study-monitoring, they don't sell data analysis—they do one thing, and **they want to do it as well as it can possibly be done. They want to do it as good as it can possibly be done. And that's a great model for us.**”



Kayentis Europe

4 route de la Noue
91190 Gif-sur-Yvette – France
Phone: +33 (0)1 69 18 25 40
kayentis@kayentis.com

Kayentis USA

3624 Market Street, Suite 5E
Philadelphia, PA 19104 – USA
Phone: + (1) 215 966 6088
kayentis@kayentis.com